Eton Pharmaceuticals (ETON) Short term Debt (2020 - 2025)

Eton Pharmaceuticals has disclosed Short term Debt across 6 years of filings, most recently posting $8.8 million for Q4 2025.

• Short term Debt for Q4 2025 came in at $8.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $8.8 million (changed N/A YoY), and the FY2025 annual result was $8.8 million, changed N/A from the prior year.
• Short term Debt came in at $8.8 million for Q4 2025 at Eton Pharmaceuticals, up from $2.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $8.8 million in Q4 2025 to a low of $364000.0 in Q2 2022.
• The 5-year median for Short term Debt is $1.5 million (2023), against an average of $2.6 million.
• Across the five-year window, Short term Debt tumbled 51.4% in 2022 and jumped 420.81% in 2023, its largest moves.
• Eton Pharmaceuticals' Short term Debt stood at $1.4 million in 2021, then slipped by 27.15% to $1.0 million in 2022, then surged by 420.81% to $5.4 million in 2023, then decreased by 23.33% to $4.1 million in 2024, then surged by 113.07% to $8.8 million in 2025.
• The last three Short term Debt figures came in at $8.8 million (Q4 2025), $2.8 million (Q3 2025), and $2.8 million (Q2 2025), per Business Quant data.